Targeting SYK to alleviate MDSC-driven immunosuppression and augment anti-PD1 efficacy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Myeloid-derived suppressor cells (MDSCs) are key mediators of tumor immune suppression and resistance to immune checkpoint blockade (ICB) therapies.
• Current strategies to target MDSCs are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the role of spleen tyrosine kinase (SYK) in tumor progression and immune suppression.
• To evaluate SYK inhibition as a therapeutic strategy to enhance anti-PD-1 immunotherapy.

Main Methods:

• Correlation analysis of SYK activity with tumor progression in human cancers.
• Utilized a SYK gain-of-function mouse model (SYK^S544Y) in carcinogen-induced and xenograft cancer models.
• Investigated SYK's mechanism of action via the JAK-STAT-CXCR2 signaling axis.
• Assessed the efficacy of pharmacological SYK inhibition alone and in combination with anti-PD-1 therapy in preclinical models and patient-derived tumor organoids.

Main Results:

• SYK activity positively correlated with tumor progression in human cancers.
• Activated SYK promoted tumorigenesis across multiple cancer types, primarily through MDSC-dependent mechanisms.
• SYK activation enhanced MDSC migration and suppressed anti-tumor T cell responses by activating the JAK-STAT-CXCR2 pathway.
• SYK inhibition reduced tumor growth and potentiated anti-PD-1 therapy efficacy in mouse and patient-derived organoid models.

Conclusions:

• SYK plays a critical immunoregulatory role in promoting tumor progression.
• Targeting SYK is a promising strategy to modulate the tumor microenvironment.
• SYK inhibition can enhance the effectiveness of checkpoint blockade immunotherapy, offering a new avenue for cancer treatment.